<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191123045472N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-13</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of CWD and ICW tympanomastoidectomy with endoscopic control to evaluate residual cholesteatoma for patients with middle and mastoid cholesteatoma</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of residual cholesteatoma in two methods of tympanomastoidectomy  CWD and ICW with endoscopic control in patients with middle ear and mastoid cholesteatoma</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2011-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/43763</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization type is blocked randomization. Foursquare blocks of intervention group(A) and control(B) are defined on cards 1-6 (AABB,ABAB,ABBA,BBAA,BABA,BAAB), the cards are placed inside the envelope. Then the cards are selected randomly and then the random string is created from the sequence of selected cards. Patients in the intervention and control group are included in the study according to this sequence, Blinding description: The study is single-blind. In the informed consent, it is mentioned that the patients will be treated randomly in one of two methods (both are the standard method and the same postoperative appearance), so patients are unaware of which group they are involved in.</study_design>
      <phase>3</phase>
      <hc_freetext>Tympanomastoidectomy in people with cholesteatoma.</hc_freetext>
      <i_freetext>Intervention 1: "Intervention group": Twenty patients with cholesteatoma in the intervention group underwent CWD (tympanomastoidectomy with posterior wall resection) without chain reconstruction. Posterior wall resection (CWD) is a standard surgical treatment for cholesteatoma, but it has many complications. After surgery, patients were examined microscopically at 3, 6, 9, and 12 months, and then at the 12th month, patients with local anesthesia and sedation underwent middle ear surgery and, if possible, chain reconstruction. Midterm surgery was performed to check for pearl and residual cholesteatoma using a 30 ° and 2.7 mm endoscope, and recurrence rate was recorded. Mann-Whitney and Fisher's exact tests were used for data analysis. Intervention 2: "Control group:" In the control group, twenty patients with surgical candidate cholesteatoma underwent endoscopic ICW (tympanomastoidectomy with posterior wall preservation). This procedure has fewer complications, but access to middle ear rosettes is more difficult than CWD. In this study, an endoscope was used to access ear rosettes that are not accessible by microscope.After surgery, patients were examined microscopically at 3, 6, 9, and 12 months, and then at the 12th month, patients with local anesthesia and sedation underwent middle ear surgery and, if possible, chain reconstruction. Midterm surgery was performed to check for pearl and residual cholesteatoma using a 30 ° and 2.7 mm endoscope, and recurrence rate was recorded. Mann-Whitney and Fisher's exact tests were used for data analysis.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no data available yet.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Pedram Borghei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>AmirAlam hospital, North Saadi Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1145765111</zip>
        <telephone>+98 21 6634 9253</telephone>
        <email>entrc.tums@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Pedram Borghei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>AmirAlam hospital , North Saadi Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1145765111</zip>
        <telephone>+98 21 6634 9253</telephone>
        <email>entrc.tums@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who were diagnosed with microscopic examination of cholesteatoma and who were candidates for surgery, with any hearing loss</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patient with cholesteatoma with posterior wall destruction
The patient does not follow-up or postoperative follow-up examinations for any reason.
The patient has complications of cholesteatoma, such as dizziness, facial paralysis, sensorineural hearing loss average or above average, intracranial complications, mastoid abscess, lateral sinus thrombosis, etc
The patient should be treated with revision
Failure after graft surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H71</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cholesteatoma of middle ear</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>"Intervention group": Twenty patients with cholesteatoma in the intervention group underwent CWD (tympanomastoidectomy with posterior wall resection) without chain reconstruction. Posterior wall resection (CWD) is a standard surgical treatment for cholesteatoma, but it has many complications. After surgery, patients were examined microscopically at 3, 6, 9, and 12 months, and then at the 12th month, patients with local anesthesia and sedation underwent middle ear surgery and, if possible, chain reconstruction. Midterm surgery was performed to check for pearl and residual cholesteatoma using a 30 ° and 2.7 mm endoscope, and recurrence rate was recorded. Mann-Whitney and Fisher's exact tests were used for data analysis.</i_keyword>
      <i_keyword>"Control group:" In the control group, twenty patients with surgical candidate cholesteatoma underwent endoscopic ICW (tympanomastoidectomy with posterior wall preservation). This procedure has fewer complications, but access to middle ear rosettes is more difficult than CWD. In this study, an endoscope was used to access ear rosettes that are not accessible by microscope.After surgery, patients were examined microscopically at 3, 6, 9, and 12 months, and then at the 12th month, patients with local anesthesia and sedation underwent middle ear surgery and, if possible, chain reconstruction. Midterm surgery was performed to check for pearl and residual cholesteatoma using a 30 ° and 2.7 mm endoscope, and recurrence rate was recorded. Mann-Whitney and Fisher's exact tests were used for data analysis.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of remaining cholesteatoma. Timepoint: 3 months, 6 months, 9 months and 12 months. Method of measurement: Endoscope 30 ° and 7.2 mm.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2006-06-18</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for Research, Tehran University of Medical Sciences, Ghods St,Keshavarz Blvd Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
